Ad
related to: lupus testing false negative rate of cologuard results- Dosing Information
For HCPs: find LUPKYNIS® dosing
and administration recommendations.
- Safety & Efficacy Profile
View LUPKYNIS® results in clinical
trials. Adverse reaction info.
- Connect with a REP
Sign up to receive updates and
HCP materials for LUPKYNIS®.
- Starting LUPKYNIS®
Get info and resources to help
start your patient on LUPKYNIS®.
- Dosing Information
Search results
Results from the WOW.Com Content Network
The false positive rate (FPR) is the proportion of all negatives that still yield positive test outcomes, i.e., the conditional probability of a positive test result given an event that was not present. The false positive rate is equal to the significance level. The specificity of the test is equal to 1 minus the false positive rate.
Thus, one or more of the following tests are generally performed to detect lupus anticoagulant if a high suspicion remains, and/or specify lupus anticoagulant as the cause of an abnormal mixing test: Phospholipid-sensitive functional clotting testing, such as the dilute Russell's viper venom time, Kaolin clotting time, or silica clotting time. [13]
The probability of type I errors is called the "false reject rate" (FRR) or false non-match rate (FNMR), while the probability of type II errors is called the "false accept rate" (FAR) or false match rate (FMR). If the system is designed to rarely match suspects then the probability of type II errors can be called the "false alarm rate". On the ...
Top-Line Data Show Exact Sciences' Cologuard Test Demonstrates 92 Percent Sensitivity in the Detection of Colorectal Cancer All endpoints achieved in 10,000-patient trial of non-invasive ...
For premium support please call: 800-290-4726 more ways to reach us
Antinuclear antibody (ANA) testing and anti-extractable nuclear antigen form the mainstay of serologic testing for SLE. ANA testing for lupus is highly sensitive, with the vast majority of individuals with Lupus testing positive; but the test is not specific, as a positive result may or may not be indicative of Lupus. [100]
The company reported $1.43 billion in revenue last year from its screening business, primarily from sales of its colon cancer test Cologuard, which was approved by the FDA in 2014.
The kinetoplast fluoresces if serum contains high avidity anti-dsDNA antibodies. This test has a higher specificity than EIA because it uses unprocessed DNA. Processed DNA can contain regions of ssDNA, allowing detection of anti-ssDNA antibodies, which can give false positive results. [1] [28]
Ad
related to: lupus testing false negative rate of cologuard results